Cannabis Market News: CV Sciences Diversifies Portfolio; CBDistillery’s CBN Entry; More
Executive Summary
CV Sciences aims to offset COVID-19 impacts with its new Happy Lane CBD product line, targeted to the value retail channel, as well as CV Acute, its first immunity-support product that contains no CBD, a departure for the firm as it seeks new growth opportunities. More cannabis news in brief.
You may also be interested in...
US FDA Showed ‘Several’ Cards In CBD Bill Comments – CV Sciences’ Duffy MacKay
In itself, the proposed US Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 may be of little consequence. But the FDA’s October comments on the bill were revealing, CV Sciences’ Duffy MacKay says.
CV Sciences’ Q1 Sales Tumble, And COVID-19’s Only Part Of The Problem
Store closures in the natural product channel did no favors for CV Sciences in March, but the 45% decrease in its first-quarter sales reflects pressures that were weighing on its consumer business before the pandemic struck. The PlusCBD product manufacturer remains confident about its long-term prospects in what it expects to be a more sensibly regulated marketplace versus the status quo.
CBD Drugs In Cosmetic Clothing Violate California’s Unfair Competition Law – Class Actions
California federal courts have shown themselves receptive to proposed class actions alleging that purported cosmetics carrying unapproved drug claims violate the state’s Unfair Competition Law. Plaintiffs now are testing similar theories in suits against marketers of CBD-infused topical products.